Magnolo Lucia, Noto Davide, Cefalù Angelo B, Averna Maurizio, Calandra Sebastiano, Yao Zemin, Tarugi Patrizia
Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Department of Internal Medicine and Medical Specialities, University of Palermo, Palermo, Italy.
Biochim Biophys Acta. 2016 Apr;1861(4):371-9. doi: 10.1016/j.bbalip.2016.01.014. Epub 2016 Jan 26.
We have previously identified a deletion mutant of human apoB [apoB (Thr26_Tyr27del)] in a subject with primary hypobetalipoproteinemia. The present study determined the effect of Thr26_Tyr27del mutation on apoB secretion using transfected McA-RH7777 cells. Transient or stable transfection of apoB-48 containing the Thr26_Tyr27del mutation showed drastically reduced secretion of the mutant as compared to wild-type apoB-48. No lipoproteins containing the mutant apoB-48 were secreted into the medium. Incubation of transfected cells in a lipid-rich medium in the presence of cycloheximide showed rapid turnover of cell-associated mutant apoB-48 as compared to that of wild-type apoB-48. Immunofluorescence experiments showed that the mutant apoB-48 was mostly localized in the endoplasmic reticulum. Treatment with the proteasomal inhibitor MG132 markedly attenuated the turnover of cell-associated mutant apoB-48, whereas treatment with inhibitors of autophagosomal/lysosomal function (e.g. 3-MA or ammonium chloride) had no effect. Taken together, these results indicated that the defective secretion of the Thr26_Tyr27del mutant was associated with increased intracellular degradation of apoB through the proteasome-dependent pathway.